Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: A Danish cohort study

Objective The optimal duration and dose of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer (CRC) have not been established. We examined this issue in the Danish Diet, Cancer, and Health Study. Methods Self-reported NSAID use at...

Full description

Saved in:
Bibliographic Details
Published in:Cancer causes & control 2009-07, Vol.20 (5), p.731-740
Main Authors: Friis, Søren, Poulsen, Aslak H, Sørensen, Henrik Toft, Tjønneland, Anne, Overvad, Kim, Vogel, Ulla, McLaughlin, Joseph K, Blot, William J, Olsen, Jørgen H
Format: Article
Language:English
Subjects:
Adenoma
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Aspirin
Aspirin - therapeutic use
Biomedical and Life Sciences
Biomedicine
Body mass index
Cancer Research
Cancer therapies
Cohort analysis
Cohort Studies
Colorectal cancer
Colorectal Neoplasms - epidemiology
Colorectal Neoplasms - prevention & control
Denmark
Dosage
Drug dosages
Drug prescriptions
Epidemiology
Female
Hematology
Hospitals
Humans
Male
Middle Aged
Nonsteroidal antiinflammatory agents
Obesity
Oncology
Original Paper
Pills
Prescription drugs
Public Health
Questionnaires
Tumors
Writing tablets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The optimal duration and dose of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer (CRC) have not been established. We examined this issue in the Danish Diet, Cancer, and Health Study. Methods Self-reported NSAID use at entry (January 1995-May 1997) was updated through June 2006, using a nationwide prescription database. CRC incidence was ascertained from nationwide registers. Cox proportional hazards regression was used to compute confounder-adjusted incidence rate ratios (RRs) and 95% confidence intervals (CIs). Results From 51,053 cohort subjects, we identified 615 CRC cases during 1995-2006. Daily aspirin use at entry was associated with a decreased risk of CRC (RR, 0.73; 95% CI, 0.49-1.10). A similar risk reduction was seen among subjects with 10 or more prescriptions for aspirin or non-aspirin NSAIDs and five or more years of follow-up. Most aspirin prescriptions were for 75-150 mg aspirin tablets. Among non-aspirin NSAID users, only those with body mass index (BMI) above 25 showed risk reductions [RR, 0.69 (0.47-1.03) for 10 or more prescriptions]. Conclusions Long-term consistent use of aspirin or non-aspirin NSAIDs appears necessary to achieve a protective effect against CRC. Further studies of the effective dose of aspirin and the potential interaction between NSAID use and BMI are warranted.
ISSN:0957-5243
1573-7225
DOI:10.1007/s10552-008-9286-7